$INNV Innovus Pharmaceuticals, Inc. ("Innovus Ph
Post# of 405
(Total Views: 599)
Posted On: 03/04/2019 7:15:37 AM
$INNV
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that received approval from Health Canada to market its product RecalMax™ as a Natural Health Product (“NHP”), for the indications to temporarily relieve symptoms of mental fatigue and sensation of weakness and support cognitive functions including mental focus and stamina. The product will be available as an over-the-counter (“OTC”) or behind the counter product and will not require a prescription.
“We have built an impressive commercial pipeline in Canada,” said Dr. Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma. “Our product pipeline is adding significant revenues from the Canadian market and now rivals Canadian companies with established sales force which is a testament to our powerful sales and marketing platform,” continued Dr. Damaj.
RecalMax™ is our twelfth product approved in Canada including Zestra®, Zestra Glide® and Uxor™ (EjectDelay®) marketed by Orimed Pharma, UriVarx® through our partnership with Acerus Pharmaceuticals Corporation and Vesele®, Apeaz®, Xyralid® Cream, ProstaGorx®, Xyralid® Suppositories, BH™ Testosterone Booster and Diabasens®. In addition, we have one other product: PEVarx® that has an application submitted and is being reviewed currently by Health Canada for potential approval and several other products expected to be filed in the future.”
About RecalMax™
RecalMax™ is a Natural Health Product approved by Health Canada to temporarily relieve symptoms of mental fatigue and sensation of weakness and support cognitive functions including mental focus and stamina and is a dietary supplement in the United States to support brain health.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.
For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.vesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.xyralid.com; www.fluticare.com; www.allervarx.com; www.apeaz.com; www.mzssleepingaid.com, www.novalere.com and www.diabasens.com.
Innovus Pharma's Forward-Looking Safe Harbor:
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that received approval from Health Canada to market its product RecalMax™ as a Natural Health Product (“NHP”), for the indications to temporarily relieve symptoms of mental fatigue and sensation of weakness and support cognitive functions including mental focus and stamina. The product will be available as an over-the-counter (“OTC”) or behind the counter product and will not require a prescription.
“We have built an impressive commercial pipeline in Canada,” said Dr. Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma. “Our product pipeline is adding significant revenues from the Canadian market and now rivals Canadian companies with established sales force which is a testament to our powerful sales and marketing platform,” continued Dr. Damaj.
RecalMax™ is our twelfth product approved in Canada including Zestra®, Zestra Glide® and Uxor™ (EjectDelay®) marketed by Orimed Pharma, UriVarx® through our partnership with Acerus Pharmaceuticals Corporation and Vesele®, Apeaz®, Xyralid® Cream, ProstaGorx®, Xyralid® Suppositories, BH™ Testosterone Booster and Diabasens®. In addition, we have one other product: PEVarx® that has an application submitted and is being reviewed currently by Health Canada for potential approval and several other products expected to be filed in the future.”
About RecalMax™
RecalMax™ is a Natural Health Product approved by Health Canada to temporarily relieve symptoms of mental fatigue and sensation of weakness and support cognitive functions including mental focus and stamina and is a dietary supplement in the United States to support brain health.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.
For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.vesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.xyralid.com; www.fluticare.com; www.allervarx.com; www.apeaz.com; www.mzssleepingaid.com, www.novalere.com and www.diabasens.com.
Innovus Pharma's Forward-Looking Safe Harbor:
(0)
(0)